


## IN THE CLAIMS

Claims 1-21 (Cancelled)

Claim 22. (Currently amended) A method for preventing recurrence of cerebrovascular disorder in a mammal, which comprises administering an effective amount of a compound having an angiotensin II antagonistic activity, a prodrug thereof or a salt thereof to the mammal,  
~~The method according to claim 14,~~ wherein the compound having an angiotensin II antagonistic activity is a compound represented by the formula (I):



wherein  $R^1$  represents a group capable of forming an anion or being converted into said group,  $X$  indicates that the phenylene group and the phenyl group are bound to each other directly or via a spacer of a chain made of 2 or less atoms,  $n$  is an integer of 1 or 2, ring A represents a benzene ring which may further have substituent(s),  $R^2$  represents a group capable of forming an anion or being converted into said group, and  $R^3$  represents a hydrocarbon residue which may be bound via a heteroatom and may have substituent(s).

Claim 23. (Currently amended) The method according to claim 22 14, wherein the compound having an angiotensin II antagonistic activity is ~~Losartan, Eprosartan, Candesartan cilexetil, or Candesartan, Valsartan, Telmisartan, Irbesartan, Olmesartan or Tasosartan.~~

Claim 24. (Currently amended) The method according to claim 22 14, wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid.

Claim 25. (Currently amended) The method according to claim 22 14, wherein the compound having an angiotensin II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate.

Claim 26. (Currently amended) The method according to claim 22 14, wherein the compound having an angiotensin II antagonistic activity is 2-ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazole-3-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylic acid.

Claims 27-42. (Cancelled)